piracetam has been researched along with Myelodysplastic Syndromes in 1 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peyrl, A | 1 |
| Weichert, N | 1 |
| Kühl, JS | 1 |
| Ebell, W | 1 |
| Hernáiz Driever, P | 1 |
1 other study available for piracetam and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Levetiracetam as a possible cause of secondary graft failure after allogenic hematopoietic stem cell transplantation.
Topics: Adolescent; Anticonvulsants; Blood Cell Count; Graft Rejection; Hematopoietic Stem Cell Transplantat | 2015 |